首页/数据集/ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of Acute Leukemia (Sample1)

ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of Acute Leukemia (Sample1)

NIAID Data Ecosystem2026-03-10 收录

表观遗传药物机制

急性白血病治疗

数据链接：

https://data.mendeley.com/datasets/3k34cn3bdh 数据链接链接失效反馈

官方服务：

资源简介：

Sample1 THP-1 H3K4me2 ChIPSeq Data after ORY-1001 treatment

应用场景：

创建时间：

2018-03-05

急性髓系白血病

表观遗传药物机制

Pharmacological inhibition of epigenetic enzymes can have therapeutic benefit against hematological malignancies. Apart from affecting tumor cell growth and proliferation, these epigenetic agents may

NIAID Data Ecosystem50

Inhibition of EZH2 in THP-1 cells

表观遗传药物机制

白血病细胞实验

Inhibition of EZH2 in THP-1 cells

ChEBI2015-08-04 更新20

P300/CBP inhibition with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML [RNA-Seq]

肿瘤靶向治疗

表观遗传药物机制

Acute myeloid leukemia (AML) is a fatal blood cancer with cytotoxic chemotherapy offering at best 25% 5-year survival. While targeted BCL2 and FLT3 inhibitors venetoclax and gilteritinib are used upfr

NIAID Data Ecosystem10

Epigenetic evidence of an Ac/Dc axis by VPA and SAHA. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA

组蛋白修饰

表观遗传药物机制

Valproic acid (VPA) is one of the most commonly used anti-epileptic drugs with pharmacological actions on GABA and blocking voltage-gated ion channels. VPA also inhibits histone deacetylase (HDAC) act

NIAID Data Ecosystem20

H3K27me3 and H3K4me3 ChIP-seq on DMSO or MAK683 treated cancer cell

表观遗传药物机制

癌症靶向治疗

The methyltransferase Polycomb Repressive Complex 2 (PRC2), composed of EZH2, SUZ12, and EED subunits, is associated with transcriptional repression via tri-methylation of histone H3 on lysine 27 resi

NIAID Data Ecosystem20

ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of Acute Leukemia (Sample1)

资源简介：

相关数据集